Growth Factor News and Research

RSS

Research study on EGFR and HER2 expressions in BTC

The epidermal growth factor receptor (EGFR) and the human epidermal growth factor receptor 2 (HER2) are involved in the carcinogenesis of many malignancies. Therapeutic molecules targeting EGFR and HER2 have been successfully used for the treatment of colorectal, breast, lung and head and neck cancers among others.

19 Oct 2009

New chromosomal abnormality in acute lymphoblastic leukemia

Researchers identified a new chromosomal abnormality in acute lymphoblastic leukemia (ALL) that appears to work in concert with another mutation to give rise to cancer. This latest anomaly is particularly common in children with Down syndrome.

19 Oct 2009

Cardium Therapeutics reports positive findings from Excellarate Phase 1/2 clinical study

Cardium Therapeutics today announced the publication of positive findings from the open label multi-center Phase 1/2 clinical study of Excellarate(TM) (GAM501, Ad5PDGF-B / 2.6% collagen), its product candidate for the potential treatment of non-healing diabetic foot ulcers.

19 Oct 2009

Findings may yield new treatments for COPD

A genetic mutation found in four children born with multiple abnormalities may provide insight into potential treatments for newborn lung distress and chronic obstructive pulmonary disease (COPD).

19 Oct 2009

Blocking newly discovered second molecular pathway may prevent angiogenesis: UCLA researchers

Researchers at the University of California Los Angeles (UCLA) have found that a second molecular pathway may need to be blocked to prevent malignant cells from creating new blood vessels [angiogenesis]. A study of patients with pancreatic cancer showed that CXCL5 may be a key molecule in the angiogenesis switch—the point at which cells stop being normal and start producing blood vessels that feed malignancy.

14 Oct 2009

Antisense Therapeutics completes repeat-dosing toxicology studies for ATL1103

Antisense Therapeutics Limited is pleased to announce that the Company has now completed repeat-dosing toxicology studies for ATL1103 in two species -- mouse and non-human primate. Draft study reports from the study contractors in the United States have been received, and the toxicology outcomes from these studies support ANP's plans for the continued development of ATL1103.

14 Oct 2009

Scientists identify the first genetic mechanism that generates the cerebral cortex

The cerebral cortex, the largest and most complex component of the brain, is unique to mammals and alone has evolved human specializations. Although at first all stem cells in charge of building the cerebral cortex-the outermost layer of neurons commonly referred to as gray matter-are created equal, soon they irrevocably commit to forming specific cortical regions. But how the stem cells' destiny is determined has remained an open question.

14 Oct 2009

Bladder cancer patients benefit from anticancer drug that is used to treat lung and colon malignancies: Study

An anticancer drug that is commonly used to treat lung and colon malignancies is having a benefit and potentially prolonging survival in patients with invasive bladder cancer, researchers reported at the 2009 Clinical Congress of the American College of Surgeons.

14 Oct 2009

Positive results from BioMimetic Therapeutics' Phase III trial comparing Augment Bone Graft to autograft

BioMimetic Therapeutics, Inc. today announced positive top-line results from its North American pivotal (Phase III) randomized controlled trial comparing its fully synthetic, off-the-shelf bone growth factor product, Augment Bone Graft (“Augment”), to autograft for use in hindfoot and ankle fusion surgery.

14 Oct 2009

Calcium to cure cardiovascular problems

Calcium is crucial for heart regeneration by cardiac stem cells following cardiovascular problems say scientists in an article to be published in the journal Circulation Research this 9th of October.

9 Oct 2009

Ethnicity plays a significant role in non-small cell lung cancer genetics: Study

Clinical research out of University Hospitals Case Medical Center has found that African Americans with a common form of lung cancer have a lower frequency of drug-sensitizing genetic mutations, which may impact response to new cancer-fighting drugs.

8 Oct 2009

ArQule completes patient enrollment in ARQ 197 Phase 2 trial for non-small cell lung cancer

ArQule, Inc. (Nasdaq: ARQL) today announced that patient enrollment in a Phase 2 trial with ARQ 197 in non-small cell lung cancer (NSCLC) has been completed.

5 Oct 2009

Bristol-Myers Squibb to present new data on BARACLUDE and other compounds at the AASLD 2009

New data on four Bristol-Myers Squibb Company (NYSE:BMY) compounds will be presented at the 60th annual meeting of the American Association for the Study of Liver Diseases (AASLD) in Boston from October 30 to November 3.

3 Oct 2009

RXi receives USPTO notices of allowance for certain siRNA sequence-specific patent applications

RXi Pharmaceuticals Corporation, a biopharmaceutical company pursuing the development and commercialization of proprietary therapeutics based on RNA interference (RNAi), today announced that Notices of Allowance were recently issued by the United States Patent Office (USPTO) on patent applications filed by Thermo Fisher Scientific Inc. and licensed to RXi Pharmaceuticals encompassing small interfering RNA (siRNA) sequences targeting superoxide dismutase (SOD1), Amyloid beta (A4) precursor protein (APP), interleukin-1 receptor-associated kinase 4 (IRAK4), hepatocyte growth factor receptor (MET protooncogene) and cyclin-dependent kinase (cdk) inhibitor p27 (also known as Kip1, CDKN1B).

From Thermo Fisher Scientific Inc. 3 Oct 2009

Cardium announces positive results from the Phase 1 / 2 clinical study of Excellarate

Cardium Therapeutics announced plans to report on preliminary safety and efficacy data from its Matrix Phase 2b Excellarate clinical study. Based on guidance from Cardium's independent clinical data management company which is currently completing the statistical analysis of all data for the Matrix clinical trial, Cardium expects to receive the locked unblinded data set and be in position to announce preliminary results on or before October 14, 2009.

3 Oct 2009

Latest optical and laser technology in medicine displayed at FiO meeting

From scopes that help premature babies breathe to techniques for imaging live neurons and beating hearts as they develop, the latest optical and laser technology being deployed in medicine and the biosciences will be on display at the Optical Society's (OSA) Annual Meeting, Frontiers in Optics (FiO), which takes place Oct. 11-15 at the Fairmont San Jose Hotel and the Sainte Claire Hotel in San Jose, Calif.

1 Oct 2009

University scientists achieve breakthrough in brain research

Chaos brews in the brains of newborns: the nerve cells are still bound only loosely to each other. Under the leadership of Academy Research Fellow Sari Lauri, a team of researchers at the University of Helsinki has been studying for years how a neural network capable of processing information effectively is created out of chaos. The team has now found a new kind of mechanism that adjusts the functional development of nerve cell contacts.

30 Sep 2009

Response Genetics launches new genetic diagnostic test for gastric cancer

Response Genetics, Inc., a company focused on the development and sale of molecular diagnostic tests for cancer, announced today the availability of its ResponseDX: Gastric™ genetic test panel, a proprietary PCR-based diagnostic test. By analyzing the expression of genes that correlate with response to commonly used chemotherapy agents, physicians can better tailor treatment for their patients with gastric cancer and gastroesophageal (GE) junction cancer.

29 Sep 2009

Pfizer to commence Phase 3 trial of oral c-Met and ALK inhibitor

Pfizer Oncology announced today that it will initiate a global, Phase 3 clinical trial of its investigational oral c-Met and ALK inhibitor, PF-02341066, versus standard of care chemotherapy in patients with advanced non-small cell lung cancer (NSCLC) carrying the ALK (anaplastic lymphoma kinases) fusion gene, who have progressed on one prior treatment with a platinum-based chemotherapy.

26 Sep 2009

New method found for the treatment of pancreatic cancer

For the first time researchers have shown that by inhibiting the action of an enzyme called TAK-1, it is possible to make pancreatic cancer cells sensitive to chemotherapy, opening the way for the development of a new drug to treat the disease.

24 Sep 2009

Growth Factor News and Research

Research study on EGFR and HER2 expressions in BTC

New chromosomal abnormality in acute lymphoblastic leukemia

Cardium Therapeutics reports positive findings from Excellarate Phase 1/2 clinical study

Findings may yield new treatments for COPD

Blocking newly discovered second molecular pathway may prevent angiogenesis: UCLA researchers

Antisense Therapeutics completes repeat-dosing toxicology studies for ATL1103

Scientists identify the first genetic mechanism that generates the cerebral cortex

Bladder cancer patients benefit from anticancer drug that is used to treat lung and colon malignancies: Study

Positive results from BioMimetic Therapeutics' Phase III trial comparing Augment Bone Graft to autograft

Calcium to cure cardiovascular problems

Ethnicity plays a significant role in non-small cell lung cancer genetics: Study

ArQule completes patient enrollment in ARQ 197 Phase 2 trial for non-small cell lung cancer

Bristol-Myers Squibb to present new data on BARACLUDE and other compounds at the AASLD 2009

RXi receives USPTO notices of allowance for certain siRNA sequence-specific patent applications

Cardium announces positive results from the Phase 1 / 2 clinical study of Excellarate

Latest optical and laser technology in medicine displayed at FiO meeting

University scientists achieve breakthrough in brain research

Response Genetics launches new genetic diagnostic test for gastric cancer

Pfizer to commence Phase 3 trial of oral c-Met and ALK inhibitor

New method found for the treatment of pancreatic cancer

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Applications Engineer

Latest News